Amgen's Repatha Gets Broad EU Label, But FDA May Not Follow Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Given the tenor of an FDA advisory committee review in June, the U.S. regulator seems likely to opt for a narrower population for the PCSK9 inhibitor than did the European Commission.